In an OncLive.com interview, ilyas sahin, MD of UF Medicine discussed the potential use of Northstar Response in patients with advanced GI #cancer undergoing active treatment.

The study was presented at the ASCO 2024 GI Cancers Symposium. #GI24

Watch: onclive.com/view/dr-sahin-…

Patient reported outcomes from the LITESPARK-005 study which showed superiority of belzutifan over everolimus in advanced RCC. Tom Powles #GU24 ASCO

Checkmate 914 part B results of adjuvant nivolumab monotherapy vs placebo in kidney cancer. No difference in DFS. #GU24 ASCO

AMBASSADOR trial results. Adjuvant pembrolizumab for Bladder Cancer. Positive DFS benefit but interim OS data shows no difference. #GU24 ASCO

PemCab study evaluating the combination of pembrolizumab and cabozantinib in cisplatin ineligible patients with metastatic UC ASCO #GU24

EV 302 subgroup analysis. Combination of enfortumab and pembrolizumab in metastatic UC seems to benefit all patients ASCO #GU24

Enfortumab vedotin as monotherapy in patients with #mCRPC : Results of stage I of a phase 2 trial. Presentation by Umang Swami Huntsman Cancer Institute. #GU24 written coverage by Rashid K. Sayyid University of Toronto > bit.ly/42f1P0D ASCO

Did somebody say cake? Join us in the poster hall at 11:30 to celebrate 20 years of advancing science & transforming pt care! 🎂🍰 #GU24

Good morning #GU24 ! Let's go day 1!

Selecting Patients for Frontline CDK4/6 Inhibitors in Metastatic Breast Cancer ascopubs.org/doi/10.1200/AD… #asco #asco dailynews #bcsm #MedTwitter #breastcancer ASCO MD Anderson Cancer Center

In an OncLive.com interview, UF Health oncologist Brian Ramnaraign, MD FACP discussed findings from a single-institution review of the incidence of immunotherapy-related toxicities in older patients with kidney #cancer :

onclive.com/view/dr-ramnar…

Great Oral Abstract Session earlier today at #IKCSNA23 with presentation of the STELLAR-001 study with Sumanta K. Pal, MD, FASCO and the LITESPARK-013 study with pooja ghatalia as well as discussion on germline susceptibility of #kidneycancer and models of NF2 loss in HLRCC Kidney Cancer